CAJ | 학술논문

目的骨化三醇联用缬沙坦对减少2型糖尿病肾病患者蛋白尿的有效性与安全性评估。方法选取62例住院及门诊2型糖尿病肾病患者，随机分为骨化三醇组（VD3），缬沙坦组(ARB)，和联合治疗组(ARB+VD3)，观察8w，测定患者治疗前后尿蛋白，肾功能，血钙。结果治疗后ARB组尿蛋白，VD3组尿蛋白较基线下降（P<0.05）,联合治疗组尿蛋白较基线明显下降（P<0.01）,较之ARB组及 VD3组其下降更为明显，差异有统计学意义（均P<0.05）。所有患者均无明显不良反应，未发生高钙血症。结论骨化三醇联合缬沙坦可以有效降低糖尿病肾病患者的蛋白尿，保护肾功能，疗效优于单独用药。
목적골화삼순련용힐사탄대감소2형당뇨병신병환자단백뇨적유효성여안전성평고。방법선취62례주원급문진2형당뇨병신병환자，수궤분위골화삼순조（VD3），힐사탄조(ARB)，화연합치료조(ARB+VD3)，관찰8w，측정환자치료전후뇨단백，신공능，혈개。결과치료후ARB조뇨단백，VD3조뇨단백교기선하강（P<0.05）,연합치료조뇨단백교기선명현하강（P<0.01）,교지ARB조급 VD3조기하강경위명현，차이유통계학의의（균P<0.05）。소유환자균무명현불량반응，미발생고개혈증。결론골화삼순연합힐사탄가이유효강저당뇨병신병환자적단백뇨，보호신공능，료효우우단독용약。
Objective To assess the effectiveness and safety of calcitriol combined with Valsartan in the treatment of type 2 diabetic kidney disease . Methods We conducted a randomized controlled trial, by which 62 patients with type 2 diabetic kidney disease were randomly assigned to calcitriol group (VD3),Valsartan group (ARB)or combined treatment group (ARB+VD3). The end points were assessed at 8 weeks, including 24-hour urinary protein, renal function and blood calcium.Results At 8 weeks after treatment, 24-hour urinary protein levels were significantly reduced in each group, compared with that before treatment (P<0.05).24-hour urinary protein level in combined treatment was significantly lower than that in calcitriol group and valsartan group (P<0.05). No side effects such as hypercalcemia were observed in all patients. Conclusion combined treatment with calcitriol and valsartan can effectively alleviate proteinuria and protect renal function.